Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NLN | Q9BYT8 | 1/20 | 0.64 |
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | METAP1 | P53582 | 1/20 | 0.45 |
| ▸ | TPH1 | P17752 | 2/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | FCER2 | P06734 | 1/20 | 0.41 |
| ▸ | MC5R | P33032 | 2/20 | 0.40 |
| ▸ | MC1R | Q01726 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23573037 | 1.00 | NLN (0.64) | NLNMETAP2METAP1TPH1FAAH | |
| SCHEMBL23573035 | 1.00 | NLN (0.64) | NLNMETAP2METAP1TPH1FAAH | |
| SCHEMBL23572984 | 0.89 | NLN (0.51) | NLN | |
| SCHEMBL21794934 | 0.89 | NLN (0.51) | NLN | |
| SCHEMBL21794972 | 0.89 | NLN (0.51) | NLN | |
| SCHEMBL23572993 | 0.86 | EGFR (0.50) | NLN | |
| SCHEMBL2445252 | 0.86 | EGFR (0.50) | NLN | |
| SCHEMBL21794951 | 0.82 | NLN (0.47) | NLN | |
| SCHEMBL23572972 | 0.82 | NLN (0.47) | NLN | |
| SCHEMBL21794974 | 0.82 | NLN (0.47) | NLN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331333-B2 | Enhancers of neurolysin activity | TEXAS TECH UNIVERSITY SYSTEM (US) | 2025-06-17 | — | — | US | disclosed |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | TEXAS TECH UNIVERSITY SYSTEM | 2021-07-01 | — | — | US | disclosed |
| WO-2020047185-A9 | ENHANCERS OF NEUROLYSIN ACTIVITY | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-09-17 | — | — | WO | disclosed |
| WO-2020047185-A1 | ENHANCERS OF NEUROLYSIN ACTIVITY | TEXAS TECH UNIVERSITY SYSTEM (US) | 2020-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12331333-B2 | Enhancers of neurolysin activity | GAP43, NLN, BDNF | NLN 2/4885METAP2 545/4885METAP1 286/4885 |
| US-20210198647-A1 | Enhancers of Neurolysin Activity | GAP43, NLN, BDNF | NLN 2/4885METAP2 545/4885METAP1 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.